Sector News

Pfizer abandons plan to split into two companies

September 26, 2016
Life sciences

U.S. drugmaker Pfizer Inc, which has been considering a split into two companies for more than two years, said on Monday it will not do so because the move would not create any shareholder value.

Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split down the road if “factors materially change at some point in the future.”

Pfizer said on Monday the decision would not have an impact on its 2016 financial forecast.

The decision not to create two publicly traded companies follows the collapse of its planned $160 billion acquisition of Allergan Inc after a change in tax law took away the tax benefits of the deal.

Investors were expecting the company to step back from the split, Sanford Bernstein analyst Tim Anderson said in a research note.

“Where to from here? The company seems likely to leave open its option for a future split-up, but more immediately it may continue hunting for M&A targets,” Anderson wrote.

Pfizer’s shares were down 1.2 percent to $33.85 in premarket trading on Monday.

The pharma giant began openly planning for the possible split in early 2014, saying it would operate the businesses as separate divisions and track their progress for three years before reaching a decision. In August, it said a decision would be made by year-end.

Pfizer said the sum-of-the-parts analysis showed no benefit to shareholders, and that tax costs and business disruptions were factors it considered.

The company had considered the move largely because its patent-protected medicines routinely enjoy sales growth while sales in the generics portfolio usually declined.

Investors shifted their focus to whether Pfizer would split after the company terminated the deal for Irish drugmaker Allergan in April.

In August Pfizer announced it was buying cancer drugmaker Medivation Inc for $14 billion to get access to blockbuster prostate cancer drug Xtandi for its growing oncology roster.

The Medivation deal illustrates a shift in Pfizer’s mergers and acquisitions strategy from lowering taxes, which was the rationale behind the failed Allergan tax inversion deal, to strengthening its lineup of branded drugs, especially lucrative cancer treatments.

A year ago, Pfizer paid $15 billion for Hospira, which sells generic hospital products and is developing biosimilars to compete with big-selling injectable biotech drugs. That deal was seen by Wall Street as a way of bolstering its generic drugs operation ahead of potentially divesting the business.

By Natalie Grover and Caroline Humer

Source: Reuters

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach